Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097254 | 0.90 | NPSR1 (0.42) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL979558 | 0.88 | NPSR1 (0.38) | PFKFB2NSD2PFKFB1PFKFB3DOT1L | |
| SCHEMBL10097246 | 0.87 | PFKFB2 (0.47) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL10096731 | 0.86 | PFKFB2 (0.46) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL10095593 | 0.86 | PGR (0.42) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL10095919 | 0.85 | PFKFB2 (0.46) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL10256415 | 0.84 | PTPN1 (0.44) | ADORA2ANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL10096212 | 0.83 | PFKFB2 (0.44) | PGRPFKFB2NSD2PFKFB1PFKFB3 | |
| SCHEMBL10096388 | 0.83 | RAB9A (0.45) | PFKFB2NSD2PFKFB1PFKFB3DOT1L | |
| SCHEMBL10095410 | 0.83 | CYP11B2 (0.46) | PGRLMNATP53KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | PGR 3811/4885PFKFB2 4129/4885NSD2 3586/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | PGR 3813/4885PFKFB2 4202/4885NSD2 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.